• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Infectious Disease

BNT162b2 mRNA vaccine shows benefit against symptomatic and asymptomatic SARS-CoV-2 infection 

byNeel MistryandTeddy Guo
June 25, 2021
in Infectious Disease, Public Health, Pulmonology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Vaccinated individuals reported fewer SARS-CoV-2 infections and a lesser proportion of cases were symptomatic compared to the unvaccinated cohort.

2. BNT162b2 mRNA vaccine showed an effectiveness of 70% 21 days after a single dose.

Evidence Rating Level: 2 (Good) 

Study Rundown: The BNT162b2 mRNA (Pfizer-BioNTech) and ChAdOx1 nCoV-19 adenoviral (Oxford-AstraZeneca) COVID-19 vaccines have been rapidly rolled out in the UK since December 2020. However, population-level vaccine effectiveness studies are needed to assess the impact of coronavirus vaccination and inform developments of public health policy. This prospective cohort study (SIREN) aimed to describe factors associated with both BNT162b2 and ChAdOx1 nCoV-19 vaccine coverage and early effectiveness of the BNT162b2 vaccine against symptomatic and asymptomatic infection in a large-scale cohort of healthcare workers in UK. The primary outcome for vaccine coverage analysis was the binary ever vaccinated variable (defined as having Âł 1 vaccine dose recorded between Dec 8, 2020, and Feb 5, 2021), while that for vaccine effectiveness analysis was PCR-confirmed SARS-CoV-2 infection (defined as a new PCR positive result for the negative cohort and reinfection in the positive cohort at the time of follow-up). According to study results, the BNT162b2 vaccine was effective against both symptomatic and asymptomatic SARS-CoV-2 infection in working-age adults. A limitation of this study may be the lack of objective functional assessments, such as baseline respiratory function, as the major outcomes considered were recorded through online questionnaires. Nonetheless, it provides valuable insight into the effectiveness of the BNT162b2 vaccine in a population-level cohort.

Click to read the study in The Lancet

Relevant Reading: Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

RELATED REPORTS

Worsening kidney function observed following SARS-CoV-2 infection in children

The 2 Minute Medicine Podcast Episode 55

The Scan by 2 Minute Medicine®: Triple Attack Against Endometriosis, Vaccines and Autism, Revisited, The Final Frontier of Human Health, and Eating Well to Live Better:

In-depth [prospective cohort]: By Dec 7, 2020, 29 378 patients were assessed for eligibility across 104 hospital sites in the UK. Included patients were healthcare workers, support staff, and administrative staff (aged ≥18 years) who provided written consent and were able to complete the 12-month follow-up. Those with no PCR tests or insufficient PCR and antibody data were excluded. Altogether, 23 324 patients (8203 [35%] in the positive cohort and 15 121 [65%] in the negative cohort) met the inclusion criteria. The median patient age was 46.1 years (interquartile range [IQR] 36.0-54.1) and majority (84%) were female.

The total follow-up time was from Dec 7, 2020, to Feb 5, 2021, equivalent to 1 106 905 person-days (396 318 person-days vaccinated and 710 587 person-days unvaccinated). By Feb 5, 2021, 89% of patients (n=20 641) received at least one dose, with 94% receiving the BNT162b2 vaccine. Having a previous infection (adjusted odds ratio [aOR] 0.59, 95% confidence interval [CI] 0.54-0.64), being female (aOR 0.72, 95% CI 0.63-0.82), and age < 35 (aOR 0.78, 95% CI 0.64-0.96) were associated with significantly lower vaccine coverage. Compared to the vaccinated group, the unvaccinated group reported a substantially greater number of new infections (71 cases vs. 977 cases) during follow-up (adjusted hazard ratio 0.30, 95% CI 0.15-0.45). In the unvaccinated cohort, 543 (56%) patients had typical COVID-19 symptoms and 140 (14%) were asymptomatic 14 days prior to PCR-positive result, compared with 29 (36%) and 15 (19%) in the vaccinated cohort. A single dose of the BNT162b2 vaccine showed 70% (95% CI 55-85) effectiveness after three weeks. Findings from this study suggest that a single dose provides substantial efficacy against both symptomatic and asymptomatic COVID-19 infections.

Image: PD 

©2021 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: bnt162b2ChAdOx1 nCoV-2 vaccineCoronaviruscovidCOVID-19 antibodiescovid-19 diagnosiscovid-19 infectionCOVID-19 reinfectionCOVID-19 VaccinemRNA vaccineSARS-CoV-2vaccinevaccine schedule
Previous Post

Early intervention for cerebral palsy should begin at diagnosis or in children meeting high risk criteria – International Clinical Practice Guideline

Next Post

#VisualAbstract: Tocilizumab may improve survival in COVID-19 patients with hypoxia and systemic inflammation

RelatedReports

Being overweight and obese associated with increased incidence of chronic kidney disease
Chronic Disease

Worsening kidney function observed following SARS-CoV-2 infection in children

May 23, 2025
The 2 Minute Medicine Podcast Episode 15
2MM Podcast

The 2 Minute Medicine Podcast Episode 55

April 5, 2025
The Scan by 2 Minute Medicine: The Role of Virtual Reality in Pain Management, WHO’S controversial diagnosis on gaming addictions, the TikTok ban and psychology of doom scrolling, and the risk of smart devices replacing annual checkups
The Scan by 2 Minute Medicine®

The Scan by 2 Minute Medicine®: Triple Attack Against Endometriosis, Vaccines and Autism, Revisited, The Final Frontier of Human Health, and Eating Well to Live Better:

April 1, 2025
The 2 Minute Medicine Podcast Episode 15
2MM Podcast

The 2 Minute Medicine Podcast Episode 54

March 21, 2025
Next Post
#VisualAbstract: Rifapentine-moxifloxacin noninferior to standard of care treatment for pulmonary tuberculosis

#VisualAbstract: Tocilizumab may improve survival in COVID-19 patients with hypoxia and systemic inflammation

Standardized developmental screening of refugee children is recommended

Internet based training intervention for teachers effective as a strategy to improve cardiorespiratory fitness of children

Fewer work hours linked to greater likelihood of continued breastfeeding

Fortification of breast milk with preterm formula powder vs human milk fortifier in preterm neonates

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Seventh cervical nerve neurotomy may augment speech therapy in patients with chronic aphasia post-stroke
  • Time-restricted eating does not confer changes in sleep, mood, or quality of life
  • Commonly cited medication triggers may not increase risk of microscopic colitis among older adults
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.